Global Snake Antivenom Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Snake Antivenom Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Snake antivenom is a medication made up of antibodies used to treat snake bites by venomous snakes. It is a type of antivenom.

Market Overview:

The latest research study on the global Snake Antivenom market finds that the global Snake Antivenom market reached a value of USD 2405.0 million in 2022. It’s expected that the market will achieve USD 3500.73 million by 2028, exhibiting a CAGR of 6.46% during the forecast period.

Company Overview:

BTG plc is one of the major players operating in the Snake Antivenom market, holding a share of 43.11% in 2023.

BTG plc

BTG plc supplies emergency medicines commonly used in emergency departments and intensive care units to treat patients with limited treatment options. BTG plc is committed to delivering quality medicines that make a real difference to patients and their families through the development, manufacture and commercialization of pharmaceutical products. BTG plc's current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with certain heart and cancer drugs.

Pfizer

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.

Key Companies in the global Snake Antivenom market covered in Chapter 3:

Bioclon Institute
South Africa Vaccine Producers
Boehringer Ingelheim
Haffkine Bio - Pharmaceutical Corporation Limited
CSL Limited
Pfizer
BTG plc
Inosan Biopharma
VINS Bio Products Limited
MicroPharm

In Chapter 4 and Chapter 14.2, on the basis of types, the Snake Antivenom market from 2018 to 2029 is primarily split into:

Polyvalent Heterologous
Monovalent Heterologous
Homologous
Other

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Snake Antivenom market from 2018 to 2029 covers:

Hospitals
Clinics
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)